• 1
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 2
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 3
    Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47: 4350.
  • 4
    Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37: 5006.
  • 5
    Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008; 46: 7884.
  • 6
    Marcellin P, Jensen DM, Hadziyannis SJ, Ferenci P. Differentiation of early virologic response (EVR) into RVR, complete EVR (CEVR) and partial EVR (PEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40kd) (Pegasys) and ribavirin (Copegus). Hepatology 2007; 46: 818A. Abstract 1308.
  • 7
    Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? J Hepatol 2007; 47: 5807.
  • 8
    Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon α2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 96470.
  • 9
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 10
    Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 42533.
  • 11
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 64552.
  • 12
    Shiffman ML, Rodriguez-Torres M, Gordon SC, et al. Rapid virologic response is enhanced by higher drug exposure among patients receiving taribavirin in combination with pegylated interferon alfa-2b for the treatment of HCV infection. Hepatology 2006; 44(4 suppl 1): 616A. Abstract 1146.
  • 13
    Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK, and the International Hepatitis Interventional Therapy Group. Clinical implications of testing viral response during ribavirin and peginterferon α-2b treatment for hepatitis C. Hepatology 2002; 36(suppl 1): 281A. Abstract 472.
  • 14
    Reddy KR, Rakela J, Lopez-Talavera JC, Pockros PJ. Correlations between rapid virologic response, early virologic response and sustained virologic response in HCV genotype 1 patients treated with pegylated interferon alfa-2a and ribavirin. Gastroenterology 2005; 128(4 suppl 2): A-716. Abstract S1540.
  • 15
    De Segadas-Soares JA, Villela-Nogueira CA, Perez RM, Nabuco LC, Brandao-Mello CE, Coelho HSM. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis C patients treated with peginterferon-alpha2b and ribavirin? J Clin Gastroenterol 2009; 43: 3626.
  • 16
    Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 95460.
  • 17
    Berg T, Von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 108697.
  • 18
    Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 45160.
  • 19
    Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 4518.
  • 20
    Sulkowski M, Lawitz E, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 21
    Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 188493.
  • 22
    Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 12605.
  • 23
    Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 260917.
  • 24
    Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 3542.
  • 25
    Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 12434.
  • 26
    Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 5227.
  • 27
    Mecenate F, Barbaro G, Pellicelli A, et al. Comparison of interferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the CLEO trial. Presented at: 58th Annual Meeting of the American Association of the Study of Liver Diseases; November 2–6, 2007; Boston, MA.
  • 28
    Yu M-L, Dai C-Y, Huang J-F, et al. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 5539.
  • 29
    Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? Hepatology 2007; 46(suppl 1): S6. Abstract 8.
  • 30
    Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 183745.
  • 31
    Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97103.
  • 32
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 33
    Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 168894.
  • 34
    SP Europe. PegIntron [Summary of Product Characteristics]. Bruxelles, Belgium: SP Europe, 2008.
  • 35
    Roche Registration Limited. Pegasys [Summary of Product Characteristics]. Welwyn Garden City, UK: Roche Registration Limited, 2008.
  • 36
    Schering Corporation. PegIntron (Peginterferon Alfa-2b) Injection. Kenilworth, NJ: Schering Corporation, 2008.
  • 37
    Hoffman-LaRoche, Inc. Pegasys (Peginterferon Alfa-2a). Nutley, NJ: Hoffmann-La Roche Inc., 2004.
  • 38
    Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46: 42031.
  • 39
    Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alfa-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 173240.